Likewise, MMP-1 and MMP-3 levels in RA patients and synovial fibroblast-like cells in vitro have suggested that iguratimod can significantly lower their concentration with clinically and experimentally established doses.82 The MMPs actively destroy the cartilage during RA, and their attenuation leads to bone protection. This evidence concerns the gene MMP1 and rheumatoid arthritis.